The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero
PhaseBio Pharmaceuticals Inc (PHAS)

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Co.'s lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. Co. is also developing PB1046, a fusion protein in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension.

Company Name:  PhaseBio Pharmaceuticals Inc
Website:  www.phasebio.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PHAS:  3
Total Market Value Held by ETFs:  $2.56M
Total Market Capitalization:  $314.00M
% of Market Cap. Held by ETFs:  0.82%
April 19, 2019    10:24 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes



Strong Buy (3.75 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

PhaseBio Pharmaceuticals Inc (PHAS) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2019, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.